Biblio

Author Title [ Type

] Year

Filters: Author is Peng, Jun [Clear All Filters]

Journal Article

Hua M, Li J, Wang C, Shao L, Hou M, Peng J, Feng Q. Aberrant expression of microRNA in CD4 cells contributes to Th17/Treg imbalance in primary immune thrombocytopenia. Thromb Res. 2019;177:70-78.

Huang Q-S, Liu Y, Wang J-B, Peng J, Hou M, Liu H, Feng R, Wang J-W, Xu L-P, Wang Y, et al. All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Haematol. 2021;8(10):e688-e699.

Xie X, Chen J, Wo D, Ma E, Ning Y, Peng J, Zhu W, Ren D-N. Babao Dan is a robust anti-tumor agent via inhibiting wnt/β-catenin activation and cancer cell stemness. J Ethnopharmacol. 2021:114449.

Pei Y, Peng J, Behl M, Sipes NS, Shockley KR, Rao MS, Tice RR, Zeng X. Comparative neurotoxicity screening in Human iPSC-derived neural stem Cells, Neurons and Astrocytes. Brain Res. 2015.

Peng J, Liu B, Ma Q-L, Luo X-J. Dysfunctional endothelial progenitor cells in cardiovascular diseases: role of NADPH oxidase. J Cardiovasc Pharmacol. 2014.

Wang Y, Zhang J, Su Y, Wang C, Zhang G, Liu X, Chen Q, Lv M, Chang Y, Peng J, et al. miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia. Mol Ther Nucleic Acids. 2020;20:764-776.

Wu Y-J, Hou M, Liu H-X, Peng J, Ma L-M, Yang L-H, Feng R, Liu H, Liu Y, Feng J, et al. A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Adv. 2020;4(22):5846-5857.

Zhao P, Hou M, Liu Y, Liu H-X, Bin Huang R-, Yao H-X, Niu T, Peng J, Jiang M, Han Y-Q, et al. Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. Platelets. 2020:1-9.

Sun S, Gao N, Hu X, Luo H, Peng J, Xia Y. SOD3 overexpression alleviates cerebral ischemia-reperfusion injury in rats. Mol Genet Genomic Med. 2019:e831.

Ma J, Ning Y-N, Xu M, Hou Y, Wang N, Hou X-Y, Yu Y-Y, Li H, He W-D, Shao L-L, et al. Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia. Blood. 2013.